Century Therapeutics (IPSC) Total Liabilities (2020 - 2026)

Century Therapeutics (IPSC) has reported Total Liabilities for 7 consecutive years, with $61.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Liabilities fell 17.77% year-over-year to $61.8 million; the TTM figure through Mar 2026 stood at $61.8 million (down 17.77% YoY), while the FY2025 annual figure was $64.8 million, down 66.24% from the prior year.
• Total Liabilities slipped to $61.8 million in Q1 2026 per IPSC's latest filing, from $64.8 million in the prior quarter.
• Across five years, Total Liabilities topped out at $194.3 million in Q2 2024 and bottomed at $61.8 million in Q1 2026.
• Historically, Total Liabilities has averaged $147.1 million across 5 years, with a median of $174.6 million in 2022.
• Annual changes were most pronounced in 2022 — Total Liabilities surged 346.81% — and 2025, when it sank 66.24%.
• Century Therapeutics' Total Liabilities stood at $183.8 million in 2022, then fell by 4.28% to $175.9 million in 2023, then climbed by 9.04% to $191.9 million in 2024, then tumbled by 66.24% to $64.8 million in 2025, then retreated by 4.57% to $61.8 million in 2026.
• Business Quant data shows IPSC's Total Liabilities at $61.8 million in Q1 2026, $64.8 million in Q4 2025, and $68.4 million in Q3 2025.